FDA approves drug that can delay onset of type 1 diabetes

Nov. 22, 2022
FDA approval.

The U.S. Food and Drug Administration approved Tzield (teplizumab-mzwv) injection to delay the onset of stage 3 type 1 diabetes in adults and pediatric patients 8 years and older who currently have stage 2 type 1 diabetes.

Tzield binds to certain immune system cells and delays progression to stage 3 type 1 diabetes. Tzield may deactivate the immune cells that attack insulin-producing cells, while increasing the proportion of cells that help moderate the immune response. Tzield is administered by intravenous infusion once daily for 14 consecutive days. 

FDA release

By WindyNight on Adobe Stock
adobestock_296464233
ID 296570530 © Vetre Antanaviciute-meskauskiene | Dreamstime.com
dreamstime_xxl_296570530
ID 357182116 © LaTerase | Dreamstime.com
dreamstime_xxl_357182116
ID 125346528 © KaterynaNovikova | Dreamstime.com
dreamstime_xxl_125346528